MedPath

Hypertension Control Program in Argentina (HCPIA)

Not Applicable
Completed
Conditions
Hypertension
Interventions
Behavioral: Comprehensive Intervention
Registration Number
NCT01834131
Lead Sponsor
Tulane University
Brief Summary

The objective of this cluster randomized trial is to test whether a comprehensive intervention program within a national public primary care system will improve hypertension control among uninsured hypertensive patients and their families in Argentina.

Detailed Description

Background: Although the efficacy and effectiveness of lifestyle modifications and antihypertensive pharmaceutical treatment for the prevention and control of hypertension and concomitant cardiovascular disease and premature death have been demonstrated in randomized controlled trials, this scientific knowledge has not been fully applied in the general population, especially in low and middle income countries.

Objectives: To test whether a comprehensive intervention program within a national public primary care system will improve hypertension control among uninsured hypertensive patients and their families in Argentina

Design: Cluster randomized trial

Study Participants: 1,890 study participants from 18 primary care clinics within a public primary care network in Argentina will be recruited. Patients with hypertension from the participating clinics, their spouses, and their adult hypertensive family members will be enrolled.

Intervention: Nine clinics with approximately 945 participants will be randomly assigned to the comprehensive intervention group and 9 clinics with similar participants to the usual care group. The comprehensive intervention, including health care provider education, a home-based intervention among patients and their families (lifestyle modification and home blood pressure \[BP\] monitoring) delivered by community health workers, and a mobile health intervention, will last for 18 months.

Outcomes: BP and other indicators will be measured at baseline and months 6, 12, and 18 during follow-up using standard methods. The primary outcome is a net change in systolic (SBP) and diastolic BP (DBP) from baseline to month 18 between the intervention and control groups among hypertensive study participants. The secondary outcomes are the proportion of hypertensive patients with adequate BP control (BP\<140/90 mmHg), cost-effectiveness of hypertension control, and net BP changes in normotensive participants.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
1954
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Comprehensive InterventionComprehensive Intervention1. Physicians will receive training in the use of treatment algorithms based on hypertension guidelines. 2. Community health workers (CHW) will be trained in facilitating behavioral change through BP monitoring, medication management, and lifestyle modifications. CHW will serve as a source of education, motivation, and social support, and as facilitators of healthcare utilization for participants. CHW will conduct home visits, schedule appointments with primary care physicians, deliver antihypertensive medications to patients' homes, and provide tailored counseling to address barriers to behavior change. 3. Individualized text messages to promote lifestyle changes and reminders to reinforce medication adherence will be sent to participants weekly.
Primary Outcome Measures
NameTimeMethod
Net change in systolic (SBP) and diastolic BP (DBP) from baseline to month 18 between the intervention and control groups among hypertensive study participants.Baseline and 18 months

Three BP measurements will be obtained at each data collection visit by study nurses who are masked to clinic assignment. BP will be measured according to a standard protocol recommended by the American Heart Association. The average of the three measurements will be used to compare the change over 18 months between the intervention and control groups.

Secondary Outcome Measures
NameTimeMethod
Proportion of hypertension control (BP<140/90 mmHg) among hypertensive patientsBaseline and 18 months

The proportion of hypertensives with blood pressure control (defined as (BP\<140/90 mmHg or \< 130/80 mmHg if patient has diabetes of CKD) will be compared between the intervention and control group.

Self-reported medication adherence among hypertensive patientsBaseline and 18 months

The Morisky scale questionnaire will be administered at baseline and 18 months of follow-up to compare medication adherence between the intervention and control groups.

Cost-effectiveness of the interventionBaseline and 18 Months

All resources involved in conducting this comprehensive intervention program, as well as all patient-level costs, will be documented. Primary incremental cost effectiveness ratio (ICER) measure will be cost per mmHg of change in SBP and DBP.

Net change in systolic (SBP) and diastolic BP (DBP) from baseline to month 18 between the intervention and control groups among normotensive study participantsBaseline and 18 months

Three BP measurements will be obtained at each data collection visit by study nurses who are masked to clinic assignment. BP will be measured according to a standard protocol recommended by the American Heart Association. The average of the three measurements will be used to compare the change over 18 months between the intervention and control groups among normotensives.

Net change in body weight and waist circumference from baseline to 18 monthsBaseline and 18 months

Study nurses will take anthropometric measurements on individuals in light clothing without shoes using a standard protocol.

Intensity of treatmentBaseline and 18 months

Intensification (titration and/or addition) of antihypertensive medications,compared between the intervention and control groups after 18 months of follow-up.

Trial Locations

Locations (1)

Institute for Clinical Effectiveness and Health Policy

🇦🇷

Buenos Aires, Argentina

© Copyright 2025. All Rights Reserved by MedPath